Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stroke survivors may walk better with muscle retraining device

NCT ID NCT07041775

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a training method called MINT that helps stroke survivors reduce abnormal muscle co-activation in their legs. The goal is to improve walking speed and endurance. Researchers will enroll 72 adults who had a stroke at least 6 months ago and have moderate to severe walking problems. Participants will use a myoelectric interface to learn better muscle control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
myoelectric interface for neurorehabilitation (MINT) conditioning
What this could lead to
If it works, this could lead to a new therapy that helps stroke survivors walk faster and farther by retraining muscle control.
What could go wrong
This is an early-stage study with only 72 participants, so results may not apply to everyone. The training is non-invasive but may not improve walking for all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age at enrollment is 18 to 85 * Leg impairment from unilateral stroke at least 6 months prior to screening * Severe to moderate gait impairment (ambulatory with a maximum walking speed of 0.8 m/s, i.e., half of normal speed) * Able to stand without assistance * Clinically observable gait asymmetry * Abnormal co-activation between adductor magnus and rectus femoris (R greater than or equal to 0.5) Exclusion Criteria: * Cognitive impairment with at least moderately impaired attention on digit-span test, or unable to follow instructions of the MINT task * Visual impairment (such as hemianopia) preventing sufficient perception of the screen to play the games * Anesthesia or severe neglect in the affected leg, or visual hemineglect (score of 2 on the NIH Stroke Scale Extinction and Inattention subtest) that impairs ability to play the games * Participation in another study on the affected leg, or any pharmacological study, within 6 weeks of enrollment * Inability to understand or follow commands in English due to aphasia or other reason that makes it impossible to perform the training * Diffuse or multifocal infarcts * Substantial leg or other pain preventing participation for 60 minutes a day * Spasticity treatment (pharmacological or Botox) on the affected leg within past 3 months * Severe osteoporosis causing hip or other fractures * History of multiple falls within the last year, use of walker for balance, or falling during stance while in the lab in the first session. * Contracture limiting the range of motion of the leg * Current pregnancy * From the TMS portion of the study only: History of epilepsy in adulthood requiring antiseizure medications; recent/current alcoholism or benzodiazepine/barbiturate abuse or recent history of alcohol/benzodiazepine/barbiturate withdrawal, recent history of cocaine or amphetamine use, skull fractures or skull deficits, concussion within the last 6 months, unexplained recurring headaches, vagus nerve stimulator, cochlear implant, deep brain stimulator, intracranial/carotid stents, cardiac pacemaker/AICD.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • University of Texas Southwestern Medical Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.